Cytomegalovirus infection - Pipeline Insight, 2021
This report can be delivered to the clients within 72 hours
DelveInsight’s, “Cytomegalovirus infection - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Cytomegalovirus infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cytomegalovirus infection: Overview
Cytomegalovirus (CMV) infection is caused by the human cytomegaloviruses. These are a subgroup of infective agents who belongs to the Herpesviridae family and is closely related to the herpes group of viruses. Cytomegalovirus infection is a common herpesvirus infection with a wide range of symptoms including fever and fatigue (resembling infectious mononucleosis), swollen glands, pneumonia with hypoxemia, or low blood oxygen, and sore throat. CMV spreads by direct contact of body fluids, such as saliva, blood, urine, semen, vaginal fluids, congenital infection, and breast milk. Diagnosis of a CMV infection can be confirmed by detection of CMV-induced large inclusion bodies present in urine sediment. The currently available antivirals for CMV therapy works by inhibiting the viral DNA polymerase. The approved treatment includes: Ganciclovir, valganciclovir, cidofovir, and foscarnet, to treat diseases caused by CMV in immunocompromised patients.
'Cytomegalovirus infection - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cytomegalovirus infection pipeline landscape is provided which includes the disease overview and Cytomegalovirus infection treatment guidelines. The assessment part of the report embraces, in depth Cytomegalovirus infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cytomegalovirus infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Cytomegalovirus infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cytomegalovirus infection Emerging Drugs
Further product details are provided in the report……..
Cytomegalovirus infection: Therapeutic Assessment
This segment of the report provides insights about the different Cytomegalovirus infection drugs segregated based on following parameters that define the scope of the report, such as:
Cytomegalovirus infection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cytomegalovirus infection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cytomegalovirus infection drugs.
Cytomegalovirus infection Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Cytomegalovirus infection - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Cytomegalovirus infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cytomegalovirus infection: Overview
Cytomegalovirus (CMV) infection is caused by the human cytomegaloviruses. These are a subgroup of infective agents who belongs to the Herpesviridae family and is closely related to the herpes group of viruses. Cytomegalovirus infection is a common herpesvirus infection with a wide range of symptoms including fever and fatigue (resembling infectious mononucleosis), swollen glands, pneumonia with hypoxemia, or low blood oxygen, and sore throat. CMV spreads by direct contact of body fluids, such as saliva, blood, urine, semen, vaginal fluids, congenital infection, and breast milk. Diagnosis of a CMV infection can be confirmed by detection of CMV-induced large inclusion bodies present in urine sediment. The currently available antivirals for CMV therapy works by inhibiting the viral DNA polymerase. The approved treatment includes: Ganciclovir, valganciclovir, cidofovir, and foscarnet, to treat diseases caused by CMV in immunocompromised patients.
'Cytomegalovirus infection - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cytomegalovirus infection pipeline landscape is provided which includes the disease overview and Cytomegalovirus infection treatment guidelines. The assessment part of the report embraces, in depth Cytomegalovirus infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cytomegalovirus infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cytomegalovirus infection R&D. The therapies under development are focused on novel approaches to treat/improve Cytomegalovirus infection.
This segment of the Cytomegalovirus infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cytomegalovirus infection Emerging Drugs
- mRNA-1647: Moderna Therapeutics
- Maribavir: Takeda
Further product details are provided in the report……..
Cytomegalovirus infection: Therapeutic Assessment
This segment of the report provides insights about the different Cytomegalovirus infection drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cytomegalovirus infection
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Cytomegalovirus infection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cytomegalovirus infection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cytomegalovirus infection drugs.
Cytomegalovirus infection Report Insights
- Cytomegalovirus infection Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cytomegalovirus infection drugs?
- How many Cytomegalovirus infection drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cytomegalovirus infection?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cytomegalovirus infection therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cytomegalovirus infection and their status?
- What are the key designations that have been granted to the emerging drugs?
- Moderna Therapeutics
- Takeda
- AlloVir
- SpyBiotech
- Trinomab Biotech
- Evrys Bio
- Merck & Co
- Biotest
- Stadius Biopharma
- Citranvi Biosciences
- Xyphos
- Orbis Biosciences
- Nobelpharma
- Hookipa Biotech
- AlphaVax, Inc.
- Trellis Bioscience
- mRNA 1443
- Maribavir
- Multivirus-specific cytotoxic T lymphocytes
- Cytomegalovirus vaccine
- Anti-human Cytomegalovirus monoclonal antibody
- Research programme: sirtuin targeted therapeutics
- V 160
- Cytomegalovirus immune globulin
- MSC CMV
- Research Programme: Herpesvirus vaccines
- Research programme: MicAbody antibodies
- Ganciclovir extended release
- NPC 21
- HB-101
- AVX601
- CMV-345
Introduction
Executive Summary
Cytomegalovirus infection: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cytomegalovirus infection – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Maribavir: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
V 160: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
mRNA-1647: Moderna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
Cytomegalovirus vaccine: SpyBiotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cytomegalovirus infection Key Companies
Cytomegalovirus infection Key Products
Cytomegalovirus infection- Unmet Needs
Cytomegalovirus infection- Market Drivers and Barriers
Cytomegalovirus infection- Future Perspectives and Conclusion
Cytomegalovirus infection Analyst Views
Appendix
Executive Summary
Cytomegalovirus infection: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cytomegalovirus infection – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Maribavir: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
V 160: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
mRNA-1647: Moderna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
Cytomegalovirus vaccine: SpyBiotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cytomegalovirus infection Key Companies
Cytomegalovirus infection Key Products
Cytomegalovirus infection- Unmet Needs
Cytomegalovirus infection- Market Drivers and Barriers
Cytomegalovirus infection- Future Perspectives and Conclusion
Cytomegalovirus infection Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Cytomegalovirus infection
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Cytomegalovirus infection
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Cytomegalovirus infection
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Cytomegalovirus infection
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
